美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Apnimed

27.37

+1.746.79%

盤後：27.370.00000.00%16:35 EDT

成交量：48.04萬

成交額：1,314.91萬

市值：10.90億

市盈率：-34.26

高：29.56

開：26.60

低：26.01

收：25.63

52周最高：35.29

52周最低：16.12

股本：3,982.32萬

流通股本：1,200.00萬

量比：1.71

換手率：4.00%

股息：- -

股息率：- -

每股收益(TTM):-0.7990

每股收益(LYR):-23.7581

淨資產收益率：--

總資產收益率：-36.94%

市淨率：-3.58

市盈率(LYR):-1.15

資料載入中...

總覽公司新聞資訊公告

美股異動 | 睡眠呼吸暫停藥物研發商Apnimed(APMD.US)登陸美股市場開盤股價升逾11%

異動解讀 | Apnimed上市首日盤中大漲37.5%，IPO定價超預期引發市場追捧

睡眠呼吸暫停治療藥研發商Apnimed在擴大IPO規模後，即將迎來上市首日股價大漲

Apnimed 公司IPO定價：1200萬股普通股以每股16美元公開發行

Apnimed宣佈FDA受理AD109新藥申請，該口服研究性藥物用於治療成人阻塞性睡眠呼吸暫停

Apnimed旗下AD109在三期試驗中總體耐受性良好，口乾、失眠、噁心為常見不良事件

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/APMD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"APMD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","market":"US","secType":"STK","nameCN":"Apnimed","latestPrice":27.37,"timestamp":1787688000000,"preClose":25.63,"halted":0,"volume":480426,"hourTrading":{"tag":"盘后","latestPrice":27.37,"preClose":27.37,"latestTime":"16:35 EDT","volume":4581,"amount":125381.97,"timestamp":1787690148826,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06788919235271175,"floatShares":12000000,"shares":39823183,"eps":-0.799,"marketStatus":"盤後交易","change":1.74,"latestTime":"08-25 17:51:12 EDT","open":26.6,"high":29.56,"low":26.01,"amount":13149130.865832,"amplitude":0.13851,"askPrice":27.91,"askSize":71,"bidPrice":26.82,"bidSize":74,"shortable":3,"etf":0,"ttmEps":-0.799,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"listingDate":1785470400000,"exchange":"NASDAQ","adjPreClose":25.63,"preHourTrading":{"tag":"盘前","latestPrice":27.31,"preClose":25.63,"latestTime":"09:28 EDT","volume":3818,"amount":102162.20053799999,"timestamp":1787664489572,"change":1.68,"changeRate":0.065548,"amplitude":0.073207},"postHourTrading":{"tag":"盘后","latestPrice":27.37,"preClose":27.37,"latestTime":"16:35 EDT","volume":4581,"amount":125381.97,"timestamp":1787690148826,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.709399},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","floatShares":12000000,"roa":"-36.94%","roe":"--","lyrEps":-23.758134,"volumeRatio":1.709399,"shares":39823183,"dividePrice":0,"high":29.56,"amplitude":0.13851,"preClose":25.63,"low":26.01,"week52Low":16.12,"pbRate":"-3.58","psRate":"9.07","week52High":35.29,"institutionHeld":0,"latestPrice":27.37,"committee":0.02069,"eps":-0.799,"divideRate":0,"volume":480426,"delay":0,"ttmEps":-0.799,"open":26.6,"prevYearClose":16,"prevWeekClose":28.03,"prevMonthClose":25,"prevQuarterClose":16,"fiveDayClose":31.81,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APMD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APMD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APMD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APMD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APMD","date":"2026-08-24","current":-34.255319,"percent":0.066667,"low":-12.343549,"twenty":-9.950282,"median":-8.670383,"eighty":-7.986942,"high":-7.725991,"avg":-9.168774,"sd":1.40329,"marketCap":1553511819},"quantilePoints":[{"date":"2026-08-07","current":-8.661063,"twenty":-8.320585,"median":-7.986942,"eighty":-7.766377,"marketCap":1110270342},{"date":"2026-08-14","current":-8.943759,"twenty":-8.664791,"median":-8.256435,"eighty":-7.766377,"marketCap":1146509438},{"date":"2026-08-21","current":-12.343549,"twenty":-9.895607,"median":-8.661063,"eighty":-7.942829,"marketCap":1582331874},{"date":"2026-08-24","current":-12.118728,"twenty":-9.950282,"median":-8.670383,"eighty":-7.986942,"marketCap":1553511819}],"updateTime":1787694672741},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APMD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656639897","title":"美股異動 | 睡眠呼吸暫停藥物研發商Apnimed(APMD.US)登陸美股市場 開盤股價升逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656639897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656639897?lang=zh_tw&edition=fundamental","pubTime":"2026-08-01 00:08","pubTimestamp":1785514105,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["APMD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174858058","title":"異動解讀 | Apnimed上市首日盤中大漲37.5%，IPO定價超預期引發市場追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1174858058","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174858058?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 23:46","pubTimestamp":1785512792,"startTime":"0","endTime":"0","summary":"生物技术公司Apnimed今日盘中股价大涨37.5%，引发市场广泛关注。此前，Apnimed将IPO发行价定在每股16美元，超出14至16美元的初始定价区间上限，并将发行规模从原计划的1000万股扩大至1200万股，最终募资1.92亿美元。强劲的IPO定价和扩大的发行规模，反映出市场对其投资价值的高度认可，推动股价开盘后大幅走高，最新显示股价达到22美元，远超发行价。Apnimed总部位于马萨诸塞州剑桥市，是一家处于后期研发阶段的生物技术公司。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655601933","title":"睡眠呼吸暫停治療藥研發商Apnimed在擴大IPO規模後，即將迎來上市首日股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2655601933","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655601933?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 23:32","pubTimestamp":1785511947,"startTime":"0","endTime":"0","summary":"BUZZ-睡眠呼吸暂停治疗药研发商Apnimed在扩大IPO规模后，即将迎来上市首日股价大涨7月31日-** 处于后期研发阶段的生物技术公司ApnimedAPMD.O在IPO定价超出目标后，有望于本周五在纳斯达克上市首日股价大涨** APMD股价最新显示开盘价将达22美元，远高于16美元的发行价** 这家总部位于马萨诸塞州剑桥市的公司于周四晚间售出1200万股 (link) 股票，筹资1.92亿美","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4T43X1X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","EVR","APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133013771","title":"Apnimed 公司IPO定價：1200萬股普通股以每股16美元公開發行","url":"https://stock-news.laohu8.com/highlight/detail?id=1133013771","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133013771?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 10:11","pubTimestamp":1785463869,"startTime":"0","endTime":"0","summary":"Apnimed公司宣布其首次公开募股（IPO）定价已确定。此次发行规模为1200万股普通股，每股定价为16美元，面向公众出售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188583087","title":"Apnimed宣佈FDA受理AD109新藥申請，該口服研究性藥物用於治療成人阻塞性睡眠呼吸暫停","url":"https://stock-news.laohu8.com/highlight/detail?id=1188583087","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188583087?lang=zh_tw&edition=fundamental","pubTime":"2026-07-14 20:01","pubTimestamp":1784030488,"startTime":"0","endTime":"0","summary":"Apnimed公司宣布，美国食品药品监督管理局（FDA）已正式受理其新药AD109的申请。AD109是一种研究性口服药物，旨在用于治疗成人阻塞性睡眠呼吸暂停（OSA）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121237357","title":"Apnimed旗下AD109在三期試驗中總體耐受性良好，口乾、失眠、噁心為常見不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1121237357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121237357?lang=zh_tw&edition=fundamental","pubTime":"2026-07-14 20:01","pubTimestamp":1784030487,"startTime":"0","endTime":"0","summary":"Apnimed Inc. 宣布，其候选药物AD109在关键性三期临床试验中展现出总体良好的耐受性。数据显示，治疗过程中报告的不良事件大多为轻度至中度。其中，口干、失眠和恶心是最为常见的副作用。这些发现对于评估该药物的整体安全性特征至关重要。公司表示，详细的数据将在未来的医学会议上进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}